https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4

The 1st ILEP Symposium has come to an end. Finally, we are ready to share the official statistics of this event. Please see the attached graph and map!   We would also like to once again thank our Partners – Sanofi, Viatris and Amgen. Without them this Symposium would not be possible. Thank you so […]

We are pleased to invite you to participate in a free webinar organized by the European Atherosclerosis Society (EAS) together with The Polish Lipid Association, during which we will talk about lipid disorders and rare diseases. We will discuss issues related to the diagnosis, management, treatment and diagnosis of disorders such as familial hypercholesterolemia, familial […]

Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing cardiovascular (CV) events in patients with coronary artery disease (CAD) but produced conflicting results. The aim of this meta-analysis was to evaluate the efficacy and safety of colchicine in patients […]

Familial hypercholesterolaemia (FH) is a genetic and complex multifactorial lipid disorder, which increases the risk of premature atherosclerosis and coronary artery disease. FH is still underdiagnosed and undertreated globally and clinical strategies for the treatment and management of pediatric patients with this disorder are still far from being optimal. The objective of this position paper […]

Fig. 1. Direct potential causes of myocarditis. Myocarditis is an inflammatory disease of the myocardium that mostly affects young adults. The disease is commonly caused by viral infection, medications, autoimmune disorders, and inflammatory conditions. Nearly 50% of the cases of myocarditis are due to post-viral immune response in a setting of an identifiable or non-identifiable […]

A new paper has been published about the association of statin use in older people primary prevention group with risk of cardiovascular events and mortality. The meta-analysis provides a detailed review of existing evidence and observational studies conducted to systematize knowledge on this topic. Please feel invited to learn more about the paper here.

Role of omega-6 and omega-3 fatty acids on inflammatory pathways Based on the available evidence, we are able to delineate specific nutraceuticals that may be important in reducing markers of inflammatory response. ILEP Experts discussed the impact of nutraceuticals on the induction of inflammation. The paper can be accessed here.

ILEP Experts would like to present a meta-analysis conducted to test and determine the potential benefit in reducing cardiovascular events from administration of colchicine in patients with coronary artery disease. The results of the study bring valuable knowledge related to this alkaloid and its use. You can read the publication here.

When prof. Maciej Banach founded the International Lipid Expert Panel (ILEP) in 2015 he probably did not expect that just after 6 years it will be a worldwide recognized group of experts and simultaneously – very close friends– from almost 100 countries, working together to improve diagnosis and therapy especially in the countries, when optimal management in the field of preventive cardiology and lipid disorders is still a great challenge (e.g. CEE, SE & Asian countries). ILEP was founded in order to […]